Lipid profile in patients with lung cancer

Objective & Hypothesis:Epidemiological studies show that people with low level of total cholesterol have a greater risk of death due to cancer, predominantly lung cancer.

📊

Key Findings & Data:Fasting level of TCH, TG, LDL, VLDL, HDL, Apo (a), Apo (b), lp(a) were measured 20 male patients with newly diagnosed lung cancer and 20 healthy controls.

💡

Conclusion & Impact:As serum lipid concentration were not increase in lung cancer patients, these marker are not useful predictor for early diagnosis

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Epidemiological studies show that people with low level of total cholesterol have a greater risk of death due to cancer, predominantly lung cancer. The aim of our study was to evaluated serum level of total cholesterol (TCH), triglycerides (TG), low density lipoprotein (LDL), very low density lipoprotein(VLDL), high density lipoprotein (HDL), apoprotein A [Apo(a)], Apoprotein B [Apo(b) ] and lipoprotein A [Ip (a)] in newly diagnosed lung cancer patients. Fasting level of TCH, TG, LDL, VLDL, HDL, Apo (a), Apo (b), lp(a) were measured 20 male patients with newly diagnosed lung cancer and 20 healthy controls. Mean ages were (patient/ control) 46±9.05/43.75±11.81, smoking habits (package/year) 56±15/19.12$pm$17.33, HDL concentration was 40,5±10,45/ 36.65±5:33 mg/dL, TCH concentration 170.4±62.42/ 185.3±42.83 mg/dL, LDL -concentration 102.55±54.92/ 122.2±40.14 mg/dL, VLDL concentration 27.35$pm$24.54/31.7±16.06 mg/dL, TG concentration 114.35±5342/ 125.7±58.35 mg/dL, Apo (a) concentration 120.43±28.79/ 128.5$pm$23.66 mg/dL, Apo (b) concentration 132.99$pm$35.64/ 92.88±22.05 mg/dL, Lp (a) concentration 28.97±24.60/17.59±15.23 mg/dL. There were no found significant differences of evaluated serum lipid parameters between in lung cancer patients and controls. As serum lipid concentration were not increase in lung cancer patients, these marker are not useful predictor for early diagnosis

Özet

Epidemiyolojik çalışmalar düşük kolesterol düzeyi olanlarda kanserden, özellikle akciğer kanserinden ölüm riskinin yüksek olduğunu göstermiştir. Çalışmamızın amacı yeni tanı almış akciğer kanserli hastalarda total kollesterol (TK), trigliserid (TG), düşük dansiteli lipoprotein(LDL), çok düşük dansiteli lipoprotein(VLDL), yüksek dansiteli lipoprotein(HDL), Apoprotein A[Apo(a)], Apoprotein B[ Apo(b)], ve lipoprotein A[lp(a)] düzeylerini araştırmaktır. Bu amaçla, 20 yeni tanı almış akciğer kanserli erkek hasta, 20 yaş ve cins uyumlu sağlıklı kontrol çalışmaya alındı. Ortalama yaş (hasta/kontrol) 46±9.05/43.75±11.81 yıl, sigara öyküsü(paket/yıl) 56±15/19.12±17.33, HDL konsantrasyonu 40,5±10,45/ 36.65±5.33 mg/dL, TK konsantrasyonu 170.4±62.42/ 185.3±42.83 mg/dL,LDL konsantrasyonu 102.55±54.92/122.2±40.14 mg/dL, VLDL konsantrasyonu 27.35$pm$24.54/31.7$pm$16.06 mg/dL, TG konsantrasyonu 114.35±5342/ 125.7$pm$58.35 mg/dL, Apo (a) konsantrasyonu 120.43±28.79/ 128.5±23.66 mg/dL, Apo (b) konsantrasyonu 132.99±35.64/ 92.88$pm$22.05 mg/dL, Lp (a) konsantrasyonu 28.97±24.60/17.59±15.23 mg/dL olarak bulundu..Yapılan istatistiksel değerlendirme sonunda her iki grup arasında ölçülen parametreler açısından anlamlı bir ilişki saptanmadı. Sonuç olarak; Akciğer kanserli hastalarda serum lipid parametrelerinde değişiklik olmadığından erken tanıda yararlı bir parametre olmadığı düşünülmektedir.

🔖

Cite This Article

BUĞDAYCI, R., ÇİMEN, F., ULUBAŞ, B., ERYILMAZ, T. (2022). Lipid profile in patients with lung cancer. Anadolu Tıp Dergisi, Cilt: 5 - Sayı: 2, 80–82. https://ajindex.com/articles/438110

References (1)

Alexopoulos CG, Pournaras S, Vaslamatzis M, et al. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol 1992;30.412-416. 2-Carl A. Burtis, Edward R. Ashwood. Lipids, Lipoproteins,and Apolipoproteins. Tietz textbook of Clinical Chemistry. Third edition.Philadelphia,:WB Saunders Company 1999; 843. 3-Chang AK, Berrett-Connor E, Edelstein S. Low plasma cholesterol predicts an increased risk of lung cancer in elderly women. Prev Med 1995;557-62. 4-Eichholzer M, Stahelin HB, Gutzwiller F, Lüdin E, et al. Association of low plasma cholesterol with mortality for cancer at various sites in men.l7-y follow-up of the prospective Basel study. Am J Clin Nutrition 2000; 17(2): 569-574. 5-Jacobs D,Blackburn H Higgins M, et al.Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-60. 6-Montain CF. Revisions in the international system for staging lung cancer. Chest 1997;11:1710-23. 7-Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screedned in the multiple rise factor intervention trial. Arch Intern Med 1992;152:1490-500. 8-Schatzkin A, Hoover RN, Taylor PR, et al. Serum cholesterol and cancer in the NHANIESI epidemiologic follow up study.Lancet 1987;2:298-301. 9-Shekelle RB, Tangney CC, Rossof AH,et al. Serum cholesterol, beta-carotene, and risk of lung cancer.Epidemiology 1992;3:282-287. 10-Siemianowicz K, Gminski J, Stajszczyk M, et al. Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med 2000;6(3):307:11. 11-Siemianowicz K, Gminski J, Stajszczyk M et al.Serum total cholesterol and triglycerides levels in patients with lung cancer.Int J Mol Med 2000;5(2):201-5. 12-Smith GD, Shipley MJ, Marmot MG, et al. Plasma cholesterol concentration and mortality.The Withehall Study. JAMA 1992;267:70-6.